Tag: a clinical-stage biotechnology company commercializing a novel vaccination platform
Vaxxas raises $34 million to clinically advance needle-free vaccines, including a next-generation COVID-19 vaccine...
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, has announced it has completed a financing round which raised US$23 million (A$34 million) in new funds.
Featured Article
APS Industrial brings Siemens’ next-gen PLC to Aussie manufacturers
As the manufacturing industry advances towards greater automation and digitalisation, companies are seeking smarter and more efficient control solutions to enhance their operations.
